A Patient Experience Study With ABBV-444 for Symptom Relief and Tolerability
Latest Information Update: 17 Oct 2024
At a glance
- Drugs ABBV 444 (Primary)
- Indications Dry eyes
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
Most Recent Events
- 11 Dec 2023 Status changed from recruiting to completed.
- 13 Jul 2023 Status changed from not yet recruiting to recruiting.
- 26 Jun 2023 Planned End Date changed from 11 Oct 2023 to 31 Dec 2023.